在残疾妇女中使用宫癌查:智利跨部门研究的发现
Sergio Jara-Rosales1,2,3, Elena S Rotarou3,4
1Faculty of Health Care Sciences, School of Midwifery, Universidad San Sebastián, Los Leones Campus, Santiago 7510157, Chile.
概括
残疾女性不太可能使用帕帕尼科劳 (Pap) 测试进行宫癌查. 公共卫生政策必须解决这种差异,以促进所有女性的健康平等.
科学领域:
- 公共卫生 公共卫生
- 流行病学 流行病学
- 健康 公平 卫生 公平
背景情况:
- 通过Papanicolaou (Pap) 测试进行宫癌查对于早期检测至关重要.
- 残疾妇女在获得定期健康检查方面面临重大障碍.
- 在残疾妇女中使用帕普检测的差异需要紧急调查.
研究的目的:
- 为了比较智利残疾和无残疾妇女之间的帕普检测使用情况.
- 识别影响残疾妇女服用巴氏检测的人口统计,社会经济和健康相关因素.
主要方法:
- 分析了2022年全国社会经济特征调查的数据.
- 包括71,989名18岁至75岁的女性.
- 逻辑回归模型用于评估帕普检测的利用率,对共变量进行控制.
主要成果:
- 与非残疾女性相比,残疾女性的帕普测试使用率较低.
- 增加使用率的因素包括婚姻,年龄25到64岁,以及中等/高等教育.
- 单身,接受特殊教育或不活跃与使用率下降有关.
结论:
- 对于残疾女性来说,帕普检测查存在显著差异.
- 有针对性的公共卫生干预措施对于提高查率和实现健康平等至关重要.
- 政策制定应侧重于针对弱势群体的包容性战略.
相关概念视频
Mouse Models of Cancer Study
4.7K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
4.7K
Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Cancer Survival Analysis
863
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
863


